HeartBeam Joins European EXIT-CVD Consortium to Study At-Home ECG Monitoring

By Public Technologies
  • HeartBeam joined the European EXIT-CVD research consortium, led by University Medical Center Groningen and Royal Philips.
  • It will lead HEART-CHECK, evaluating at-home ECG monitoring for early detection and triage of cardiac events in high-risk patients discharged following ACS.
  • Its contribution will be in-kind, including devices and clinical expertise.
  • The EUR 27.6 million project is co-funded by the EU Innovative Health Initiative and industry partners, encompassing 22 studies involving over 14,000 patients.
  • The system is FDA-cleared only for arrhythmia assessment; heart attack assessment remains investigational, and HEART-CHECK use will be investigational without CE marking.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Heartbeam Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261015343006) on October 15, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.